ReNeuron Group completes first dosing of patients in study for new degenerative eye disease therapy

ReNeuron Group PLC's (LON:RENE) Michael Hunt talks to Proactive London following news on their data from their latest clinical assessment, which will be presented later this year.

Hunt talks through the phase IIa extension study of its human retinal progenitor cell therapy for degenerative eye disease.